Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934117 | 1.00 | MAPT (0.33) | MAPTALDH1A1L3MBTL1SMN1; SMN2POLB | |
| SCHEMBL4925534 | 0.74 | MAPT (0.35) | MAPTALDH1A1L3MBTL1GAAKMT2A | |
| SCHEMBL679530 | 0.74 | MAPT (0.35) | MAPTALDH1A1L3MBTL1GAAKMT2A | |
| SCHEMBL679529 | 0.74 | MAPT (0.35) | MAPTALDH1A1L3MBTL1GAAKMT2A | |
| SCHEMBL684824 | 0.72 | MAPT (0.33) | MAPTALDH1A1L3MBTL1GAAKMT2A | |
| SCHEMBL679446 | 0.72 | MAPT (0.33) | MAPTALDH1A1L3MBTL1GAAKMT2A | |
| SCHEMBL679447 | 0.72 | MAPT (0.33) | MAPTALDH1A1L3MBTL1GAAKMT2A | |
| SCHEMBL28809691 | 0.70 | KDM4E (0.48) | MAPTALDH1A1SMN1; SMN2POLBGAA | |
| SCHEMBL1432605 | 0.64 | ALDH1A1 (0.42) | MAPTALDH1A1L3MBTL1SMN1; SMN2POLB | |
| SCHEMBL11971934 | 0.61 | MAPT (0.35) | MAPTALDH1A1L3MBTL1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | CNR2, CNR1, OPRL1 | MAPT 665/4885ALDH1A1 4441/4885L3MBTL1 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.